Lee's Pharmaceutical Holdings Future Growth
Future criteria checks 1/6
Lee's Pharmaceutical Holdings is forecast to grow revenue at 16.1% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Pharmaceuticals earnings growth | 12.6% |
Revenue growth rate | 16.1% |
Future return on equity | 4.0% |
Analyst coverage | Low |
Last updated | 16 Apr 2024 |
Recent future growth updates
Recent updates
Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking
Dec 20Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01
May 21Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01
Apr 02Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01
Aug 29Does Lee's Pharmaceutical Holdings (HKG:950) Have A Healthy Balance Sheet?
Apr 05Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?
Mar 17Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?
Feb 22What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Jan 29What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?
Jan 12Have Insiders Sold Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Recently?
Dec 22Don't Ignore The Fact That This Insider Just Sold Some Shares In Lee's Pharmaceutical Holdings Limited (HKG:950)
Dec 08Is Lee's Pharmaceutical Holdings Limited's (HKG:950) Recent Price Movement Underpinned By Its Weak Fundamentals?
Dec 01Is Lee's Pharmaceutical Holdings Limited (HKG:950) A Strong Dividend Stock?
Nov 18Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 1,461 | N/A | N/A | N/A | 1 |
12/31/2024 | 1,278 | N/A | N/A | N/A | 1 |
12/31/2023 | 1,053 | 17 | -30 | 110 | N/A |
9/30/2023 | 980 | 5 | N/A | N/A | N/A |
6/30/2023 | 1,096 | 39 | -133 | 70 | N/A |
3/31/2023 | 1,165 | 39 | N/A | N/A | N/A |
12/31/2022 | 1,233 | 51 | 70 | 284 | N/A |
9/30/2022 | 1,350 | -119 | N/A | N/A | N/A |
6/30/2022 | 1,331 | -140 | 103 | 317 | N/A |
3/31/2022 | 1,308 | 1,966 | N/A | N/A | N/A |
12/31/2021 | 1,266 | 1,987 | -160 | 211 | N/A |
9/30/2021 | 1,275 | 2,176 | N/A | N/A | N/A |
6/30/2021 | 1,244 | 2,188 | -65 | 394 | N/A |
3/31/2021 | 1,227 | 130 | N/A | N/A | N/A |
12/31/2020 | 1,217 | 129 | -139 | 219 | N/A |
9/30/2020 | 1,199 | 167 | N/A | N/A | N/A |
6/30/2020 | 1,168 | 184 | -142 | 179 | N/A |
3/31/2020 | 1,209 | 118 | N/A | N/A | N/A |
12/31/2019 | 1,219 | 126 | 39 | 400 | N/A |
9/30/2019 | 1,185 | 301 | N/A | N/A | N/A |
6/30/2019 | 1,177 | 331 | -43 | 309 | N/A |
3/31/2019 | 1,139 | 395 | N/A | N/A | N/A |
12/31/2018 | 1,138 | 418 | 27 | 321 | N/A |
9/30/2018 | 1,126 | 243 | N/A | N/A | N/A |
6/30/2018 | 1,101 | 233 | 45 | 447 | N/A |
3/31/2018 | 1,064 | 256 | N/A | N/A | N/A |
12/31/2017 | 1,009 | 233 | 98 | 366 | N/A |
9/30/2017 | 981 | 245 | N/A | N/A | N/A |
6/30/2017 | 955 | 256 | N/A | 358 | N/A |
3/31/2017 | 930 | 245 | N/A | N/A | N/A |
12/31/2016 | 930 | 252 | N/A | 395 | N/A |
9/30/2016 | 911 | 259 | N/A | N/A | N/A |
6/30/2016 | 894 | 247 | N/A | 309 | N/A |
3/31/2016 | 917 | 242 | N/A | N/A | N/A |
12/31/2015 | 922 | 229 | N/A | 160 | N/A |
9/30/2015 | 976 | 221 | N/A | N/A | N/A |
6/30/2015 | 990 | 209 | N/A | 140 | N/A |
3/31/2015 | 979 | 191 | N/A | N/A | N/A |
12/31/2014 | 955 | 193 | N/A | 220 | N/A |
9/30/2014 | 874 | 175 | N/A | N/A | N/A |
6/30/2014 | 805 | 164 | N/A | 255 | N/A |
3/31/2014 | 755 | 160 | N/A | N/A | N/A |
12/31/2013 | 697 | 150 | N/A | 179 | N/A |
9/30/2013 | 658 | 140 | N/A | N/A | N/A |
6/30/2013 | 613 | 133 | N/A | 101 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 950's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if 950's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 950's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 950's revenue (16.1% per year) is forecast to grow faster than the Hong Kong market (7.9% per year).
High Growth Revenue: 950's revenue (16.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 950's Return on Equity is forecast to be low in 3 years time (4%).